Roche finished 2019 with increases in both sales and operating profit despite competition from biosimilar versions of two of its core products. Group sales were CHF 61.5 billion ($63.8 billion), up by 8% even as the cancer drugs Herceptin and Rituxan retreated following the loss of exclusivity. Roche reported an operating profit of CHF 17.5 billion on the basis of International Financial Reporting Standards, up by 19%. Net income was CHF 14 billion, up by 30%.
